BiotechTube

SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation

Phase 2/3Recruiting
0 watching 0 views this week📈 Rising
65
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Uterine Fibroids With Menorrhagia

Conditions

Uterine Fibroids With Menorrhagia

Trial Timeline

Sep 10, 2022 → Jun 1, 2026

NCT ID
NCT05442827

About SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation

SHR7280 tablets + SHR7280 tablets + PlaceboSHR7280 tablets blank preparation is a phase 2/3 stage product being developed by Jiangsu Hengrui Medicine for Uterine Fibroids With Menorrhagia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05442827. Target conditions include Uterine Fibroids With Menorrhagia.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT05442827Phase 2/3Recruiting

Competing Products

20 competing products in Uterine Fibroids With Menorrhagia

See all competitors
ProductCompanyStageHype Score
AzenosertibZentalis PharmaceuticalsPhase 2
44
Amolimogene + AmolimogeneEisaiPhase 2/3
65
Relugolix Combination TabletSumitomo PharmaPhase 3
77
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
Elagolix + 0.5 mg estradiol / 0.1 mg norethindrone acetate + 1 mg estradiol / 0.5 mg norethindrone acetate + E2/NETA placeboAbbViePhase 2
52
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for ElagolixAbbViePhase 3
77
Estradiol/Norethindrone Acetate + ElagolixAbbViePhase 3
77
Elagolix + PlaceboAbbVieApproved
85
Elagolix + Placebo + Estradiol/Norethindrone acetate (E2/NETA) + Estradiol + ProgesteroneAbbViePhase 2
52
Elagolix + Placebo for Estradiol/Norethindrone Acetate + Estradiol/Norethindrone Acetate + Placebo for ElagolixAbbViePhase 3
77
AdavosertibAstraZenecaPhase 2
52
AZD1775AstraZenecaPhase 2
52
Saizen® A + Saizen® BMerckPhase 3
77
Bintrafusp alfaMerckPhase 2
52
Pembrolizumab + LenvatinibMerckPhase 2
52
Pembrolizumab + Placebo for pembrolizumab + CisplatinMerckPhase 3
77
Pembrolizumab (Keytruda)MerckPhase 1
33
Pembrolizumab/Vibostolimab Co-Formulation + Pembrolizumab + Lenvatinib + 5-Fluorouracil + Cisplatin + Paclitaxel + Gemcitabine + Carboplatin + Docetaxel + Bevacizumab + Capecitabine + OxaliplatinMerckPhase 2
52
Zoledronic acidNovartisPhase 2
52
KLH-2109 + LeuprorelinKissei PharmaceuticalPhase 3
76

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85